journal article Jan 01, 2019

Generic drugs – The Indian scenario

View at Publisher Save 10.4103/jpgm.jpgm_420_18
Topics

No keywords indexed for this article. Browse by subject →

References
10
[1]
Kelly "The balance between innovation and competition: The Hatch-Waxman act, the 2003 amendments, and beyond" Food Drug Law J (2011)
[2]
Swain "Pharmaregulations for generic drug products in India and US: Case studies and future prospectives" Pharmaceut Reg Affairs (2014) 10.4172/2167-7689.1000119
[3]
Gota "Toward better quality of anticancer generics in India" Indian J Cancer (2014) 10.4103/0019-509x.146723
[4]
Dunne "A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study" BMC Pharmacol Toxicol (2013) 10.1186/2050-6511-14-1
[5]
Wouters "Comparing generic drug markets in Europe and the United States: Prices, volumes, and spending" Milbank Q (2017) 10.1111/1468-0009.12279
[6]
Janodia "Differences in price of medicines available from pharmaceutical companies and “Jan Aushadhi” stores" Value Health (2015) 10.1016/j.jval.2015.09.428
[7]
Andrade "Bioequivalence of generic drugs: A simple explanation for a US Food and Drug Administration requirement" J Clin Psychiatry (2015) 10.4088/jcp.15f10094
[8]
Kamath "Prescribing generic drugs using a generic name: Are we teaching it right?" Ind J Med Ethics (2016)
[9]
Godman "Policies to enhance prescribing efficiency in Europe: Findings and future implications" Front Pharmacol (2011) 10.3389/fphar.2010.00141
[10]
Marzo "Generic drugs: Myths, facts, and limitations" Ital J Med (2012) 10.1016/j.itjm.2011.10.002
Metrics
30
Citations
10
References
Details
Published
Jan 01, 2019
Vol/Issue
65(2)
Pages
67-69
Cite This Article
SS Joshi, YC Shetty, S Karande (2019). Generic drugs – The Indian scenario. Journal of Postgraduate Medicine, 65(2), 67-69. https://doi.org/10.4103/jpgm.jpgm_420_18